A
B N O R M A L hyperphosphorylation of the microtubule-associated tau protein and its incorporation into neurofibrillary tangles are major hallmarks of Alzheimer disease (AD). Until recently, only total tau protein (t-tau) as a marker of neuronal damage was detectable in cerebrospinal fluid (CSF). Elevated levels of CSF t-tau have been observed in patients with AD, 1 even in those with mild dementia, 2 compared with healthy elderly controls. However, CSF t-tau levels are of limited value in the differential diagnosis of AD, because they can be increased in other dementia disorders. [3] [4] [5] [6] [7] [8] Therefore, it appears likely that t-tau levels reflect neuronal degeneration rather than AD-specific pathophysiology. The use of antibodies to sites of tau that are specifically phosphorylated in AD may help to increase diagnostic accuracy, because the marker would be linked to a neuropathological hallmark of the disease. Detection of phosphorylated tau protein in the CSF therefore may provide a useful biomarker as outlined by the consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. 9 Recently, 3 different immunoassays were developed that reliably detect phosphorylated tau (p-tau) in the CSF. [10] [11] [12] These assays detect different sites of phosphorylation. Levels of CSF tau phosphorylated at threonine 181 were elevated in patients with AD compared with those with other dementias and healthy control subjects. 13 , 14 Itoh and colleagues 12 showed that CSF tau phosphorylated at serine 199 dis-
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criminates between subjects with AD and non-AD disorders with a sensitivity and a specificity of 85%.
Phosphorylation of tau protein at threonine 231 (ptau 231 ) appears very early in AD and precedes paired helical filament assembly. 15 A bioassay of p-tau 231 demonstrated a sensitivity of 85% and a specificity of 97% in distinguishing AD from other neurological disorders (OND). 10 These preliminary data suggest that CSF ptau 231 may be a good biochemical marker for AD. The assay detects early features of pathophysiology, might be used to track disease progression in individual patients, 16 and accurately discriminates patients with AD from neurological control subjects. 10 In the present study, we investigated in an independent patient and control sample to what extent CSF ptau 231 levels discriminate between patients with AD and those with other common causes of dementia (frontotemporal dementia [FTD] , vascular dementia [VD] , and
SUBJECTS, MATERIALS, AND METHODS

SUBJECT SELECTION
We enrolled a total of 192 subjects. Of these, 82 had probable AD ( ; and 20, VD. 20 These patients had structural and functional imaging findings consistent with the diagnoses. Twenty-six patients with OND were diagnosed as having amyotrophic lateral sclerosis (n=2), human immunodeficiency virus infection (n=1), systemic lupus erythematosus (n=1), stroke syndrome (n=3), hereditary motor and sensory neuropathy type I (n=1), Lyme borreliosis (n=3), rheumatoid arthritis (n=1), polyneuropathy (n=2), sarcoidosis (n=1), Huntington disease (n=1), progressive spasticity of unknown etiology (n=1), bulbar syndrome of unknown etiology (n=2), other psychiatric disorder (n=2), myopathy (n=1), diplopia and nystagmus (n=1), palsy of the sixth cranial nerve (n=1), essential tremor (n=1), and extrapyramidal symptoms of unknown etiology (n=1). We also included 21 HC subjects. Study subjects were recruited at the following 5 academic expert centers: the Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Department of Psychiatry, LudwigMaximilian University, Munich, Germany (38 AD, 6 FTD, 10 VD, 9 LBD, 19 OND, and 13 HC subjects); the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland (7 AD, 4 FTD, 6 VD, 5 LBD, and 7 OND subjects); the Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Japan (12 AD, 7 FTD, 4 VD, and 3 LBD subjects); the Department of Rehabilitation, Pitea River Valley Hospital, Pitea, Sweden (5 FTD subjects); and the Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, Md (25 AD, 4 FTD, and 8 HC subjects). Characteristics of the patients and controls are given in Table 1 . The protocol was approved by the local ethical committees and the institutional review boards of the participating centers. Informed consent was obtained from all subjects.
Eight of the 21 HC subjects were volunteers without any medical, neurological, or psychiatric disorder. Thirteen HC subjects were cognitively normal according to results of the battery of the Consortium to Establish a Registry for Alzheimer's Diease 21 (results within ±1 SD in all subtests). The CSF was collected while the subjects underwent spinal anesthesia for surgery of the urinary tract or lower extremities. Three of these subjects had diabetes mellitus as a substantial somatic comorbidity.
CSF SAMPLING AND ANALYSES OF TAU PROTEINS
The CSF samples were obtained by means of lumbar puncture, and aliquots were stored at −80°C until analysis. Mean±SD length of CSF storage was 4.1±4.4 years. Levels of p-tau 231 were measured using an enzyme-linked immunosorbent assay (Molecular Geriatrics Corporation, Vernon Hills, Ill) that is specific for p-tau 231 . 10 Results of experiments describing the specificity of the detection antibody CP9 for p-tau 231 have been reported. 10 The coefficients of variation calculated from the raw data were 13.6% (interassay) and 6.8% (intra-assay). For each patient, 80 µL of CSF was analyzed per well in duplicates. Repeated cycles of freezing and thawing of CSF samples did not affect the level of p-tau 231 (data not shown). Length of CSF storage did not affect ptau 231 levels in any group (, -0.15 to 0.30; PϾ. 20) .
A pool of AD CSF was made from samples of 40 individualswithclinicallydiagnosedADwhowereunrelatedtothestudy population. This AD CSF pool was used to produce a standard curve. Levels of p-tau 231 in our subjects were expressed in terms of the volume of the AD CSF pool that gave an equivalent signal, termed microliters of CSF equivalents. The plot of the standardcurveproducedwiththeADCSFpooldidnotpassthrough the origin, and consequently, extremely low p-tau 231 signals produced negative values in terms of microliters of CSF equivalents. Levels of t-tau protein were measured in duplicate using a commercially available enzyme-linked immunosorbent assay(InnotesthTau,ArtK-1032;Innogenetics,Gent,Belgium) according to the manufacturer's instructions. The coefficients of variation were less than 13% (interassay) and 11% (intra-assay). Assay operators (R.Z. and C.M.) were masked to the diagnostic category of the samples.
STATISTICAL ANALYSES
Values for p-tau 231 and t-tau differed significantly from a normal distribution by the Kolmogorov-Smirnov test. Differences in mean levels of CSF p-tau 231 and t-tau across all groups were assessed with the Kruskal-Wallis nonparametric 1-way analysis of variance. Pairwise comparisons between the AD and the other groups were performed with the Mann-Whitney test. For p-tau 231 and t-tau levels, sensitivity and specificity levels and numbers of correctly allocated cases were derived from receiver operating characteristic (ROC) curve analysis when the sum of specificity and sensitivity was maximized. Areas under the ROC curves (AUC) as measures of diagnostic accuracy were compared between p-tau 231 and t-tau levels using the algorithm of Hanley and McNeil. 22, 23 Correlations between p-tau 231 and t-tau levels and group characteristics were assessed with the Spearman rank correlation. Differences between groups with regard to age were assessed with the Mann-Whitney test, and with regard to sex distribution with the 2 test.
Lewy body dementia [LBD] ) and between patients with AD and healthy controls (HC). To our knowledge, the potential of p-tau 231 in CSF to differentiate AD from other dementias has not been studied. The discriminative power of p-tau 231 measurements was compared with that of measurements of t-tau, which has been studied as a diagnostic marker for AD.
RESULTS
CSF p-TAU 231 AND t-TAU LEVELS
As illustrated in Figure 1 , levels of p-tau 231 and t-tau were significantly increased in the AD group compared with all other groups. Because the HC group was significantly younger than the AD group, we repeated our analysis on a subgroup of 21 patients with AD and 21 HC subjects matched for age (P = .69) and sex (PϾ.99). Differences between the AD and HC subgroups remained highly significant (PϽ.001) for p-tau 231 and ttau levels. Therefore, we included all patients with AD in our analyses. Levels of CSF p-tau 231 and t-tau correlated significantly with each other in subjects with AD (Spearman = 0.82; PϽ.001), VD (Spearman = 0.78; PϽ.001), and LBD (Spearman = 0.77; PϽ.001).
CSF p-TAU 231 LEVELS ACCORDING TO AGE, SEX, MINI-MENTAL STATE EXAMINATION SCORE, AND CENTER IN THE AD GROUP
We found no significant effect of sex (P = .86) or age ( =0.05; P =.67) on levels of p-tau 231 . Levels of CSF ptau 231 did not correlate with the Mini-Mental State Examination score (Figure 2 ) ( =0.02; P=.85). Levels of p-tau 231 levels did not differ significantly between participating centers (Figure 3 ) ( 2 =1.75; P=.63).
ROC ANALYSIS
Sensitivity and specificity levels as well as percentage and absolute numbers of correctly allocated cases are given in To test for differences in diagnostic accuracy between p-tau 231 and t-tau levels, we compared the AUC values. Discriminative power between subjects with and without AD and between those with AD and all other dementing disorders was significantly higher for p-tau 231 compared with t-tau levels (PϽ.001). Diagnostic accuracy was also significantly improved using levels of ptau 231 compared with t-tau in differentiating AD and FTD (PϽ.001). We found no significant difference in the AUC between p-tau 231 and t-tau levels when AD was compared with LBD and VD. The AUC for the AD vs HC group was increased for levels of p-tau 231 compared with t-tau (P=.03). The AUC comparison was not separately tested for AD vs OND, because t-tau levels were measured only in 9 of 26 subjects in the OND group due to limited CSF volume.
COMMENT
In the present study, we investigated to what extent CSF p-tau 231 levels discriminate between subjects with AD, those with other common causes of dementia, and nondemented controls. The p-tau 231 levels discriminated with a specificity of 80.0% and a sensitivity of 90.2% between the group with clinically diagnosed AD and the combined non-AD groups. The phosphorylation of the threonine 231 epitope has been specifically implicated in the tau pathology of AD. 15 The results of our study indicate that p-tau 231 levels in CSF may be a clinically applicable biomarker for AD, reflecting an important feature of AD pathophysiology. 9 The CSF p-tau 231 levels showed an excellent discriminative power between the AD and control (HC and OND) groups, with sensitivity and specificity levels ranging from 90% to 100%. This finding, which was obtained in an independent sample, confirms previous results. 10 In our first study, we had used an AD brain extract for construction of a standard curve. 10 We subsequently found that serial dilutions of AD CSF produced a nonlinear response in the assay. To better mimic the response of patient CSF in the current assay, we used an AD CSF pool to generate a standard curve. We showed a parallelism between the AD brain extract and the AD CSF pool by performing ROC curve analysis for samples assayed with both of the standards and then comparing the AUC as a measure of diagnostic accuracy. 24 The difference in the AUC between the 2 standards was statistically insignificant. Thus, in terms of diagnostic accuracy, the standards are equivalent.
Moreover, CSF p-tau 231 levels correctly allocated 80.7% of subjects when AD was compared with other dementia disorders. Levels of p-tau 231 in the CSF were found to clearly distinguish AD from FTD, with a sensitivity of 90.2% and a specificity of 92.3%. The high level of discrimination is likely due to the fact that the biochemical and molecular signatures of tau pathology are distinctly different between the two diseases. 25 Thus, CSF p-tau 231 levels appear to be particularly accurate in discrimination between AD and FTD and may also serve this differential diagnosis in clinical practice.
We found an increase of p-tau 231 levels in some patients with VD and LBD. Concomitant AD pathology including neurofibrillary tangles has been described for a considerable number of patients with VD 26 and LBD 27 who are clinically indistinguishable from those with "pure" VD and LBD, respectively. Most likely, our VD and LBD groups were heterogeneous with regard to underlying ADpathology, resulting in an increase of p-tau 231 levels in some of the patients with VD and LBD. This decreases the discriminative power of p-tau 231 between AD and VD and between AD and LBD.
Our findings on the high discriminative power of CSF p-tau 231 level as a single biomarker between the AD and non-AD groups are consistent with those of a report on CSF tau phosphorylated at serine 199. 12 In addition, we show the potential of p-tau 231 to discriminate patients with AD from those with other relevant dementia disorders and from subjects without dementia. We found no effect of age, sex, or clinical dementia severity on levels of p-tau 231 . Moreover, investigating the applicability of p-tau 231 levels across several study sites, we found no effect of center on p-tau 231 levels.
These findings indicate that p-tau 231 levels may be a valuable marker for the clinical diagnosis of AD, irrespective of age, sex, dementia severity, and diagnostic center. We avoided a potential bias of our results because none of the diagnostic groups investigated herein was exclusively recruited by a single center.
The present study also investigated whether ptau 231 levels have a superior discriminative power compared with t-tau levels. Our CSF t-tau levels in AD and other disorders are consistent with those of previous reports. 28 Compared with t-tau levels, CSF p-tau 231 levels allowed a significantly better discrimination between the AD and the combined non-AD groups, between the AD and HC groups, and between the AD and non-AD dementia groups. In particular, p-tau 231 levels were superior to t-tau levels for distinguishing AD from FTD.
CONCLUSIONS
Our data indicate that CSF p-tau 231 levels may be a useful biological marker to differentiate patients with clinically diagnosed AD from those with OND and other dementia disorders, particularly FTD, and from HC subjects. We show that p-tau 231 levels fulfill the core criteria of a useful biomarker of AD as outlined by the consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. 9 The diagnostic accuracy of the various p-tau epitopes should be evaluated through a comparative study applying the immunoassays of the different p-tau epitopes on the same set of patients. Part of our sample is enrolled in a neuropathological program designed to confirm diagnoses and to provide subjects with autopsy-confirmed disease. Neuropathological studies in clinically well-characterized patients are warranted to further establish CSF p-tau 231 levels as a clinically applicable diagnostic tool. A biochemical marker to accurately discriminate patients with AD from healthy controls would be useful in the early diagnosis of AD. A biomarker for differential diagnosis of AD would be clinically relevant for therapeutic interventions, caregiver counseling, and prognosis. Our findings suggest that CSF p-tau 231 levels might be such a marker.
